Rigel Pharmaceuticals (FRA:RI2) Float Percentage Of Total Shares Outstanding: 97.38% (As of Jul. 01, 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.59
GF Value €24.33
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Float Percentage Of Total Shares Outstanding?

Rigel Pharmaceuticals FRA:RI2 +0.24% 76 Float Percentage Of Total Shares Outstanding is 97.38% as of Jul. 01, 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.33. The stock has 7 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Rigel Pharmaceuticals's float shares is 18.02 Mil. Rigel Pharmaceuticals's total shares outstanding is 18.50 Mil. Rigel Pharmaceuticals's float percentage of total shares outstanding is 97.38%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Rigel Pharmaceuticals's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Rigel Pharmaceuticals's Institutional Ownership is 45.04%.

FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Rigel Pharmaceuticals's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=18.02/18.50
=97.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 97.38% mean?
Rigel Pharmaceuticals (FRA:RI2) has a Float Percentage Of Total Shares Outstanding of 97.38% as of Jul. 01, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Float Percentage Of Total Shares Outstanding too high?
Rigel Pharmaceuticals' current Float Percentage Of Total Shares Outstanding is 97.38%. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Float Percentage Of Total Shares Outstanding compare to CADL and IMMX?
Rigel Pharmaceuticals' Float Percentage Of Total Shares Outstanding of 97.38% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Float Percentage Of Total Shares Outstanding is 97.38%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Float Percentage Of Total Shares Outstanding of 97.38%. The stock's GF Value™ is €24.33, compared to a current price of €33.59 — trading 38.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 97.38%. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Float Percentage Of Total Shares Outstanding is 97.38% as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.59 is trading 38.1% above its estimated GF Value™ of €24.33.

Key valuation signals for FRA:RI2:

  • Float Percentage Of Total Shares Outstanding: 97.38%
  • GF Value™: €24.33 vs. price of €33.59 (38.1% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.59
Price
€24.33
GF Value